Literature DB >> 10047431

Both CD4(+)and CD8(+)T cells are required for IFN-gamma gene expression in pancreatic islets and autoimmune diabetes development in biobreeding rats.

A El-Sheikh1, W L Suarez-Pinzon, R F Power, A Rabinovitch.   

Abstract

To study the relative roles of CD4(+)and CD8(+)T cells and their cytokine products in autoimmune diabetes development, we selectively depleted CD4(+)and CD8(+)T cells in autoimmune diabetes-prone (DP) biobreeding (BB) rats, by administrations of anti-CD2 and anti-CD8 monoclonal antibody (mAb) respectively. We then analysed cytokine mRNA expression, by PCR assay, in mononuclear leukocytes isolated from islets and spleens of control and mAb-treated DP-BB rats. Depletion of CD4(+)T cells (by anti-CD2 mAb) in blood, spleen and islets prevented diabetes development in DP-BB rats, and depletion of CD8(+)T cells (by anti-CD8 mAb) delayed and significantly decreased diabetes incidence. Depletion of either CD4(+)or CD8(+)T cells completely prevented IFN-gamma mRNA upregulation in islets of DP-BB rats above the low level expressed in islets of diabetes-resistant (DR) BB rats. Also, IL-10 mRNA levels in islets of DP-BB rats were significantly decreased by depletion of either CD4(+)or CD8(+)T cells, whereas the effects of the anti-T cell mAb on mRNA levels of other cytokines in islets (IL-2, IL-4, IL-12p40, and TNF-alpha) were discordant. In contrast, both mAb treatments significantly upregulated IL-4 and TNF-alpha mRNA levels in spleens of DP-BB rats. These results demonstrate that islet infiltration by both CD4(+)and CD8(+)T cells is required for IFN-gamma and IL-10 production in islets and beta-cell destruction. Depletion of either CD4(+)or CD8(+)T cells may prevent beta-cell destruction by decreasing IFN-gamma and IL-10 production in islets and increasing IL-4 and TNF-alpha production systemically. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047431     DOI: 10.1006/jaut.1998.0264

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  6 in total

Review 1.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

2.  Interferon-γ Limits Diabetogenic CD8+ T-Cell Effector Responses in Type 1 Diabetes.

Authors:  John P Driver; Jeremy J Racine; Cheng Ye; Deanna J Lamont; Brittney N Newby; Caroline M Leeth; Harold D Chapman; Todd M Brusko; Yi-Guang Chen; Clayton E Mathews; David V Serreze
Journal:  Diabetes       Date:  2016-12-05       Impact factor: 9.461

3.  Calcineurin/nuclear factor of activated T cells and MAPK signaling induce TNF-{alpha} gene expression in pancreatic islet endocrine cells.

Authors:  Michael C Lawrence; Bashoo Naziruddin; Marlon F Levy; Andrew Jackson; Kathleen McGlynn
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

4.  Hydrogen-bonded multilayers of tannic acid as mediators of T-cell immunity.

Authors:  Veronika Kozlovskaya; Bing Xue; Weiqi Lei; Lindsey E Padgett; Hubert M Tse; Eugenia Kharlampieva
Journal:  Adv Healthc Mater       Date:  2014-12-09       Impact factor: 9.933

5.  Regulation of type 1 diabetes development and B-cell activation in nonobese diabetic mice by early life exposure to a diabetogenic environment.

Authors:  Alessandra De Riva; Maja Wållberg; Francesca Ronchi; Richard Coulson; Andrew Sage; Lucy Thorne; Ian Goodfellow; Kathy D McCoy; Miyuki Azuma; Anne Cooke; Robert Busch
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

6.  Interleukin-35 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells.

Authors:  Zhengkang Luo; Sara Lundin; Mariela Mejia-Cordova; Imane Hassani; Martin Blixt; Daisy Hjelmqvist; Joey Lau; Daniel Espes; Per-Ola Carlsson; Stellan Sandler; Kailash Singh
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.